Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

Inclusion Criteria:

- A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC
< 70%, and postbronchodilator FEV1 ≥ 30% and < 80% predicted

- Current or former cigarette smokers

Exclusion Criteria:

- Patients who have been hospitalized for an acute COPD exacerbation within 3 months
before the first visit

- Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1

- Patient with any clinically significant respiratory conditions other than COPD,
cardiovascular conditions or mental illness

- History or presence of asthma verified from medical records

- Chronic use of oxygen therapy greater than or equal to 15 hours per day

- Patient with uncontrolled infection due to HIV and/or active hepatitis

- Patients with a history of hypersensitivity reaction to inhaled anticholinergics

- Patients with clinically significant cardiovascular conditions, including myocardial
infarction during the previous 6 months, newly diagnosed arrhythmia within the
previous 3 months, unstable angina, unstable arrhythmia that had required changes in
pharmacological therapy or other intervention.